*Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017; 377(5):431-441; 1-13 [suppl appendix].
RE-VERSE AD™=A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran.
If you have any questions about PRAXBIND or would like more information, please call Medical Information Service available 24 hours a day, 7 days a week
Praxbind® (idarucizumab) is indicated in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed:
CL-PB-100001 April 2018
Please click here for full Prescribing Information for PRAXBIND.